ASCO GU 2024

REVIEW UroToday

Viewing 1-20 of 189 articles

Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024

ASCO GU 2024: Update on Biomarkers in Renal Cell Carcinoma

ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery

ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

ASCO GU 2024: Catalysts for Change: Patient Advocacy’s Role in Drug Shortages

ASCO GU 2024: Approach to the Platinum Shortage from a Community Oncologist Perspective

ASCO GU 2024: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin with or Without Pembrolizumab for High-Risk Non–muscle-Invasive Bladder Cancer That Persists/recurs After BCG Induction

ASCO GU 2024: Advanced Urothelial Carcinoma Discussant

ASCO GU 2024: Keynote Lecture - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials

ASCO GU 2024: A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer

ASCO GU 2024: Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Re-Challenging

ASCO GU 2024: Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them?

ASCO GU 2024: Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma?

ASCO GU 2024: Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?

ASCO GU 2024: Genetic Testing in RCC: Who, When, and How?

ASCO GU 2024: Management of Non-Clear Cell Renal Cell Carcinoma

ASCO GU 2024: The Emergent Role of Theranostics in Renal Cell Carcinoma

ASCO GU 2024: Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy

ASCO GU 2024: The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy

ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15)

1
2
3
4
5
6
7
8
9
10